Email Alert | RSS

北京大学学报（医学版） ›› 2023, Vol. 55 ›› Issue (3): 456-464. doi: 10.19723/j.issn.1671-167X.2023.03.011

• 论著 • 上一篇    下一篇

2型糖尿病患者使用二甲双胍与缺血性脑卒中发病风险的队列研究

于欢,杨若彤,王斯悦,吴俊慧,王梦莹,秦雪英,吴涛,陈大方,武轶群*(),胡永华   

  1. 北京大学公共卫生学院流行病学与卫生统计学系，重大疾病流行病学教育部重点实验室(北京大学)，北京 100191
  • 收稿日期:2023-02-28 出版日期:2023-06-18 发布日期:2023-06-12
  • 通讯作者: 武轶群 E-mail:qywu118@163.com
  • 基金资助:
    国家自然科学基金(81703291)

Metformin use and risk of ischemic stroke in patients with type 2 diabetes: A cohort study

Huan YU,Ruo-tong YANG,Si-yue WANG,Jun-hui WU,Meng-ying WANG,Xue-ying QIN,Tao WU,Da-fang CHEN,Yi-qun WU*(),Yong-hua HU   

  1. Department of Epidemiology and Biostatistics, Peking University School of Public Health; Key Laboratory of Epidemiology of Major Diseases (Peking University), Ministry of Education, Beijing 100191, China
  • Received:2023-02-28 Online:2023-06-18 Published:2023-06-12
  • Contact: Yi-qun WU E-mail:qywu118@163.com
  • Supported by:
    the National Natural Science Foundation of China(81703291)

RICH HTML

 15   

PDF (PC)

179

摘要：

目的: 探索2型糖尿病患者中使用二甲双胍与缺血性脑卒中发生风险的关联。方法: 基于“北方农村地区居民常见慢性非传染性疾病家系队列”工作，采用队列研究设计，选取北京市房山区2 625例2型糖尿病患者，按照进入队列时是否使用二甲双胍，利用Cox比例风险回归模型比较不同组别随访过程中缺血性脑卒中的发生情况。使用二甲双胍的研究对象首先与所有未使用二甲双胍者进行比较，然后进一步分别与未使用降糖药者及使用其他降糖药者进行比较。结果: 纳入的2型糖尿病患者平均年龄为(59.5±8.7)岁，男性占41.9%。中位随访时间为4.5年，共发生84例缺血性脑卒中，粗发病率为6.4(95%CI: 5.0~7.7)/1 000人年。研究对象中有1 149例使用二甲双胍，1 476例未使用二甲双胍(其中593例使用其他降糖药物，883例未使用降糖药物)。与未使用二甲双胍者相比，使用二甲双胍者发生缺血型脑卒中的风险比(hazard ratio, HR)为0.58(95%CI: 0.36~0.93; P=0.024)。与使用其他降糖药组相比，HR为0.48(95%CI: 0.28~0.84; P < 0.01);与未使用降糖药组相比，HR为0.65(95%CI: 0.37~1.13; P=0.13)。在≥60岁患者中，与所有未使用二甲双胍者及使用其他降糖药者比较，二甲双胍与缺血性脑卒中的关联具有统计学意义(HR: 0.48, 95%CI: 0.25~0.92; P < 0.05)。在血糖控制良好的患者中，二甲双胍使用和较低的缺血性脑卒中发病率相关(HR: 0.32, 95%CI: 0.13~0.77; P < 0.05);在血糖控制不良的患者中，该关联均无统计学意义(HR: 0.97, 95%CI: 0.53~1.79; P>0.05);血糖控制与二甲双胍的使用对缺血性脑卒中的发生存在交互作用(P交互 < 0.05)。结论: 在我国北方农村2型糖尿病患者，尤其是在老年糖尿病患者中，二甲双胍的使用和较低的缺血性脑卒发病风险相关; 血糖控制水平和二甲双胍使用对缺血性脑卒中的发生可能存在交互作用。

关键词: 队列研究, 二甲双胍, 缺血性脑卒中, 2型糖尿病

Abstract:

Objective: To explore the association between the use of metformin and the risk of ischemic stroke in patients with type 2 diabetes. Methods: A prospective cohort study was designed from the Fangshan family cohort in Beijing. According to metformin use at baseline, 2 625 patients with type 2 diabetes in Fangshan, Beijing were divided into metformin group or non-metformin group and the incidence of ischemic stroke between the different groups during follow-up was estimated and compared by Cox proportional hazard regression model. The participants with metformin were first compared with all the parti-cipants who did not use metformin, and then were further compared with those who did not use hypoglycemic agents and those who used other hypoglycemic agents. Results: The patients with type 2 diabetes were with an average age of (59.5±8.7) years, and 41.9% of them were male. The median follow-up time was 4.5 years. A total of 84 patients developed ischemic stroke during follow-up, with a crude incidence of 6.4 (95%CI: 5.0-7.7) per 1 000 person-years. Among all the participants, 1 149 (43.8%) took metformin, 1 476 (56.2%) were metformin non-users, including 593 (22.6%) used other hypoglycemic agents, and 883 (33.6%) did not use any hypoglycemic agents. Compared with metformin non-users, the Hazard ratio (HR) for ischemic stroke in metformin users was 0.58 (95%CI: 0.36-0.93; P = 0.024). Compared with other hypoglycemic agents, HR was 0.48 (95%CI: 0.28-0.84; P < 0.01); Compared with the group without hypoglycemic agents, HR was 0.65 (95%CI: 0.37-1.13; P=0.13). The association between metformin and ischemic stroke was statistically significant in the patients ≥ 60 years old compared with all the metformin non-users and those who used other hypoglycemic agents (HR: 0.48, 95%CI: 0.25-0.92; P < 0.05). Metformin use was associated with a lower incidence of ischemic stroke in the patients with good glycemic control (0.32, 95%CI: 0.13-0.77; P < 0.05). In the patients with poor glycemic control, and the association was not statistically significant (HR: 0.97, 95%CI: 0.53-1.79; P>0.05). There was an interaction between glycemic control and metformin use on incidence of ischemic stroke (Pinteraction < 0.05). The results of the sensitivity analysis were consistent with the results in the main analysis. Conclusion: Among patients with type 2 diabetic in rural areas of northern China, metformin use was associated with lower incidence of ischemic stroke, especially in patients older than 60 years. There was an interaction between glycemic control and metformin use in the incidence of ischemic stroke.

Key words: Cohort study, Metformin, Ischemic stroke, Type 2 diabetes

中图分类号: 

  • R186.4

表1

研究对象基本特征"

Characteristics Met users (n=1 149) Non-Met users (n =1 476) Overall (n =2 625) P
Age/years, $\bar x \pm s$ 59.6 ± 8.2 59.3 ± 9.0 59.5 ± 8.7 0.41
Gender, n (%) < 0.01
  Male 419 (36.5) 681 (46.1) 1 100 (41.9)
  Female 730 (63.5) 795 (53.9) 1 525 (58.1)
Marriage, n (%) 0.05
  Married 988 (86.0) 1 285 (87.1) 2 273 (86.6)
  Unmarried 160 (13.9) 182 (12.3) 342 (13.0)
AHI/thousands yuan，M(P25, P75) 12.0 (5.0, 36.0) 14.0 (7.2, 36.0) 12.8 (6.0, 36.0) 0.06
BMI/(kg/m2)，$\bar x \pm s$ 26.5 ± 3.6 26.6 ± 6.0 26.5 ± 5.1 0.54
Obesity, n (%) 0.83
  Yes 345 (30.0) 449 (30.4) 794 (30.3)
  No 859 (70.0) 1 027 (69.6) 1 831 (69.8)
Smoking, n (%) 0.04
  Current/past smoker 442 (38.5) 624 (42.3) 1 556 (59.3)
  Never 707 (61.5) 849 (57.5) 1 066 (40.6)
Drinking, n (%) 0.32
  Current/past drinker 342 (29.8) 464 (31.4) 1 813 (69.1)
  Never 807 (70.2) 1 006 (68.2) 806 (30.7)
Habitual sports, n (%) < 0.01
  Yes 632 (55.0) 546 (37.0) 1 178 (44.9)
  No 517 (45.0) 930 (63.0) 1 447 (55.1)
Comorbidity, n (%)
  Hyperlipidemia 1 003 (87.3) 1 319 (89.4) 2 322 (88.5) 0.10
  Hypertension 487 (42.4) 727 (49.3) 1 214 (46.3) < 0.01
Family history of IS, n (%) < 0.01
  Yes 539 (46.9) 887 (60.1) 1 426 (54.3)
  No 610 (53.1) 589 (39.9) 1 199 (45.7)

表2

研究对象缺血性脑卒中发生情况"

Groups Events of IS, n Median follow-up time/years, M(P25, P75) Overall follow-up time/person-years Crude incidence rate/per 1 000 person-years, M(P25, P75)
Met users 25 4.4 (3.5, 6.4) 5 604.0 4.5 (2.7, 6.2)
Non-Met users 59 5.3 (4.2, 6.4) 7 574.0 7.8 (5.8, 9.8)
  OHA 27 4.5 (3.5, 6.4) 2 924.4 9.2 (5.8, 12.7)
  NHA 32 5.4 (4.4, 6.5) 4 649.6 6.9 (4.5, 9.3)

表3

二甲双胍使用与缺血性脑卒中的关联性分析"

Groups Events of IS, n Adjusted incidence rate/per 1 000 person-years (95%CI) HR (95%CI) P
Overall
  Non-Met users 59 7.7 (6.1-9.4) -
  Met users 25 4.5 (3.6-5.5) 0.58 (0.36-0.93) 0.02
Male
  Non-Met users 27 7.7 (6.0-9.3) -
  Met Users 8 4.1 (3.2-4.9) 0.52 (0.23-1.17) 0.11
Female
  Non-Met users 32 7.7 (6.1-9.4) -
  Met Users 17 4.8 (3.8-5.8) 0.61 (0.33-1.12) 0.11
   < 60 years old
  Non-Met users 22 7.0 (5.5-8.4) -
  Met Users 12 5.5 (4.3-6.7) 0.79 (0.38-1.63) 0.52
  ≥60 years old
  Non-Met users 37 8.1 (6.4-9.8) -
  Met Users 13 4.0 (3.1-4.8) 0.48 (0.25-0.92) 0.03

表4

二甲双胍使用组与缺血性脑卒中的关联性分析"

CharacteristicsCompared with OHA group Compared with NHA group
Events of IS, n HR (95%CI) P Events of IS, n HR (95%CI) P
Overall 52 0.48 (0.28-0.84) < 0.01 57 0.65 (0.37-1.13) 0.13
Age/years
   < 60 21 0.69 (0.29-1.67) 0.41 25 1.00 (0.42-2.35) 1.00
  ≥60 31 0.39 (0.19-0.83) 0.01 32 0.48 (023-1.00) 0.05
Gender
  Female 29 0.56 (0.26-1.20) 0.13 37 0.59 (0.29-1.18) 0.13
  Male 23 0.39 (0.16-0.95) 0.04 20 0.78 (0.30-2.00) 0.60

表5

血糖控制与使用二甲双胍对缺血性脑卒中发病风险的交互作用分析"

Glycemic control HR (95%CI) P Pinteraction
Met users vs. Non-Met users 0.01
  Under control 0.32 (0.13-0.77) < 0.01
  Lose control 0.97 (0.53-1.79) 0.92
Met users vs. OHA 0.03
  Under control 0.28 (0.10-0.77) 0.01
  Lose control 0.69 (0.34-1.37) 0.29
Met users vs. NHA < 0.01
  Under control 0.34 (0.13-0.87) 0.02
  Lose control 1.27 (0.57-2.85) 0.56
1 Zhou M , Wang H , Zeng X , et al.Mortality, morbidity, and risk factors in China and its provinces, 1990—2017: A systematic analysis for the Global Burden of Disease Study 2017[J].Lancet,2019,394(10204):1145-1158.
doi: 10.1016/S0140-6736(19)30427-1
2 Wang YJ , Li ZX , Gu HQ , et al.China stroke statistics: An update on the 2019 report from the National Center for Healthcare Quality Management in Neurological Diseases, China National Clinical Research Center for Neurological Diseases, the Chinese Stroke Association, National Center for Chronic and Non-communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention and Institute for Global Neuroscience and Stroke Collaborations[J].Stroke Vasc Neurol,2022,7(5):415-450.
doi: 10.1136/svn-2021-001374
3 Ma Q , L iR , Wang L , et al.Temporal trend and attributable risk factors of stroke burden in China, 1990—2019: An analysis for the Global Burden of Disease Study 2019[J].Lancet Public health,2021,6(12):e897-e906.
doi: 10.1016/S2468-2667(21)00228-0
4 Van STT , Sedaghat S , Carnethon MR , et al.Cerebral microvascular complications of type 2 diabetes: Stroke, cognitive dysfunction, and depression[J].Lancet Diabetes Endocrinol,2020,8(4):325-336.
doi: 10.1016/S2213-8587(19)30405-X
5 Sarwar N , Gao P , Swshasai SR , et al.Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: A collaborative meta-analysis of 102 prospective studies[J].Lancet,2010,375(9733):2215-2222.
doi: 10.1016/S0140-6736(10)60484-9
6 韩荣荣, 唐爱奇, 方杭燕, 等.2型糖尿病患者并发脑卒中的前瞻性研究[J].预防医学,2017,29(2):139-141.
doi: 10.3969/j.issn.1673-758X.2017.02.014
7 Wang L , Gao P , Zhang M , et al.Prevalence and ethnic pattern of diabetes and prediabetes in China in 2013[J].JAMA,2017,317(24):2515-2523.
doi: 10.1001/jama.2017.7596
8 Wang L , Peng W , Zhao Z , et al.Prevalence and treatment of diabetes in China, 2013—2018[J].JAMA,2021,326(24):2498-2506.
doi: 10.1001/jama.2021.22208
9 Ma RCW .Epidemiology of diabetes and diabetic complications in China[J].Diabetologia,2018,61(6):1249-1260.
doi: 10.1007/s00125-018-4557-7
10 Inzucchi SE , Bergenstal RM , Buse JB , et al.Management of hyperglycemia in type 2 diabetes, 2015: A patient-centered approach: Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes[J].Diabetes Care,2015,38(1):140-149.
doi: 10.2337/dc14-2441
11 中华医学会糖尿病学分会.中国2型糖尿病防治指南(2020年版)[J].中华糖尿病杂志,2021,13(4):95.
12 Oliveira WH , Nunes AK , França ME , et al.Effects of metformin on inflammation and short-term memory in streptozotocin-induced diabetic mice[J].Brain Res,2016,1644,149-160.
doi: 10.1016/j.brainres.2016.05.013
13 Mandwie M , Karunia J , Niaz A , et al.Metformin treatment attenuates brain inflammation and rescues PACAP/VIP neuropeptide alterations in mice fed a high-fat diet[J].Int J Mol Sci,2021,22(24):13660.
doi: 10.3390/ijms222413660
14 Asgharzadeh F , Barneh F , Fakhraie M , et al.Metformin inhibits polyphosphate-induced hyper-permeability and inflammation[J].Int Immunopharmacol,2021,99,107937.
doi: 10.1016/j.intimp.2021.107937
15 Ismail HF , Didari T , Baeeri M , et al.Metformin attenuates brain injury by inhibiting inflammation and regulating tight junction proteins in septic rats[J].Cell J,2020,22(Suppl 1):S29-S37.
16 Pescador N , Francisco V , Vázquez P , et al.Metformin reduces macrophage HIF1α-dependent proinflammatory signaling to restore brown adipocyte function in vitro[J].Redox Biol,2021,48,102171.
doi: 10.1016/j.redox.2021.102171
17 Xiang X , Zhou L , Lin Z , et al.Metformin regulates macrophage polarization via the Shh signaling pathway to improve pulmonary vascular development in bronchopulmonary dysplasia[J].IUBMB life,2022,74(3):259-271.
doi: 10.1002/iub.2588
18 Katila N , Bhurtel S , Park PH , et al.Activation of AMPK/aPKCζ/CREB pathway by metformin is associated with upregulation of GDNF and dopamine[J].Biochem Pharmacol,2020,180,114193.
doi: 10.1016/j.bcp.2020.114193
19 Ghadernezhad N , Khalaj L , Pazoki-toroudi H , et al.Metformin pretreatment enhanced learning and memory in cerebral forebrain ischaemia: The role of the AMPK/BDNF/P70SK signalling pathway[J].Pharm Biol,2016,54(10):2211-2219.
doi: 10.3109/13880209.2016.1150306
20 Yuan R , Wang Y , Li Q , et al.Metformin reduces neuronal damage and promotes neuroblast proliferation and differentiation in a cerebral ischemia/reperfusion rat model[J].Neuroreport,2019,30(3):232-240.
doi: 10.1097/WNR.0000000000001190
21 Ahmed S , Mahmood Z , Javed A , et al.Effect of metformin on adult hippocampal neurogenesis: Comparison with donepezil and links to cognition[J].J Mol Neurosci,2017,62(1):88-98.
doi: 10.1007/s12031-017-0915-z
22 Sharma S , Nozohouri S , Vaidya B , et al.Repurposing metformin to treat age-related neurodegenerative disorders and ischemic stroke[J].Life Sci,2021,274,119343.
doi: 10.1016/j.lfs.2021.119343
23 UK Prospective Diabetes Study (UKPDS) Group .Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)[J].Lancet,1998,352(9131):854-865.
doi: 10.1016/S0140-6736(98)07037-8
24 Griffin SJ , Leaver JK , Irving GJ .Impact of metformin on cardiovascular disease: A meta-analysis of randomised trials among people with type 2 diabetes[J].Diabetologia,2017,60(9):1620-1629.
doi: 10.1007/s00125-017-4337-9
25 Benn M , Emanuelsson F , Tybjærg-hansen A , et al.Impact of high glucose levels and glucose lowering on risk of ischaemic stroke: A mendelian randomisation study and meta-analysis[J].Diabetologia,2021,64(7):1492-1503.
doi: 10.1007/s00125-021-05436-0
26 Roumie CL , Hung AM , Greevy RA , et al.Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: A cohort study[J].Ann Intern Med,2012,157(9):601-610.
doi: 10.7326/0003-4819-157-9-201211060-00003
27 Holman RR , Paul SK , Bethel MA , et al.10-year follow-up of intensive glucose control in type 2 diabetes[J].N Engl J Med,2008,359(15):1577-1589.
doi: 10.1056/NEJMoa0806470
28 Cryer DR , Nicholas SP , Henry DH , et al.Comparative outcomes study of metformin intervention versus conventional approach the COSMIC approach study[J].Diabetes Care,2005,28(3):539-543.
doi: 10.2337/diacare.28.3.539
29 Kooy A , De JJ , Lehert P , et al.Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus[J].Arch Intern Med,2009,169(6):616-625.
doi: 10.1001/archinternmed.2009.20
30 Gram J , Henriksen JE , Grodum E , et al.Pharmacological treatment of the pathogenetic defects in type 2 diabetes: The randomized multicenter South Danish diabetes study[J].Diabetes Care,2011,34(1):27-33.
doi: 10.2337/dc10-0531
31 王梦莹, 任涛, 吴涛, 等.北方农村地区居民常见慢性非传染性疾病的家系队列研究进展[J].中华流行病学杂志,2018,39(1):4.
32 Glueck DH .Sample size calculations in clinical research[J].Biometrics,2008,64(4):1307-1308.
doi: 10.1111/j.1541-0420.2008.01138_10.x
33 Matsumoto M , Harada S , Iida M , et al.Validity assessment of self-reported medication use for hypertension, diabetes, and dyslipidemia in a pharmacoepidemiologic study by comparison with health insurance claims[J].J Epidemiol,2021,31(9):495-502.
doi: 10.2188/jea.JE20200089
34 中华医学会糖尿病学分会.中国2型糖尿病防治指南(2017年版)[J].中国实用内科杂志,2018,38(4):53.
35 Chen R , Ovbiagele B , Feng W .Diabetes and stroke: Epidemiology, pathophysiology, pharmaceuticals and outcomes[J].Am J Med Sci,2016,351(4):380-386.
doi: 10.1016/j.amjms.2016.01.011
36 Roumie CL , Chipman J , Min JY , et al.Association of treatment with metformin vs sulfonylurea with major adverse cardiovascular events among patients with diabetes and reduced kidney function[J].JAMA,2019,322(12):1167-1177.
doi: 10.1001/jama.2019.13206
37 Douros A , Dell'aniello S , Yu OHY , et al.Sulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events: Population based cohort study[J].BMJ,2018,362,k2693.
38 Chen TH , Li YR , Chen SW , et al.Sodium-glucose cotransporter 2 inhibitor versus metformin as first-line therapy in patients with type 2 diabetes mellitus: A multi-institution database study[J].Cardiovasc Diabetol,2020,19(1):189.
doi: 10.1186/s12933-020-01169-3
39 Sato A , Sunayama J , Okada M , et al.Glioma-initiating cell elimination by metformin activation of FOXO3 via AMPK[J].Stem Cells Transl Med,2012,1(11):811-824.
doi: 10.5966/sctm.2012-0058
40 Chiang MC , Cheng YC , Chen SJ , et al.Metformin activation of AMPK-dependent pathways is neuroprotective in human neural stem cells against amyloid-beta-induced mitochondrial dysfunction[J].Exp Cell Res,2016,347(2):322-331.
doi: 10.1016/j.yexcr.2016.08.013
41 Isoda K , Young JL , Zirlik A , et al.Metformin inhibits proinflammatory responses and nuclear factor-kappaB in human vascular wall cells[J].Arterioscler Thromb Vasc Biol,2006,26(3):611-617.
doi: 10.1161/01.ATV.0000201938.78044.75
42 Liu Y , Tang G , Li Y , et al.Metformin attenuates blood-brain barrier disruption in mice following middle cerebral artery occlusion[J].J Neuroinflammation,2014,11,177.
doi: 10.1186/s12974-014-0177-4
43 Campvell JM , Bellman SM , Stephenson MD , et al.Metformin reduces all-cause mortality and diseases of ageing independent of its effect on diabetes control: A systematic review and meta-analysis[J].Ageing Res Rev,2017,40,31-44.
doi: 10.1016/j.arr.2017.08.003
[1] 张晓悦,林雨欣,蒋莹,张蓝超,董芒艳,池海谊,董浩宇,马利军,李智婧,常春. 自我效能在2型糖尿病患者自我管理能力和自我管理行为间的中介效应[J]. 北京大学学报（医学版）, 2023, 55(3): 450-455.
[2] 马涛,李艳辉,陈曼曼,马莹,高迪,陈力,马奇,张奕,刘婕妤,王鑫鑫,董彦会,马军. 青春期启动提前与儿童肥胖类型的关联研究: 基于横断面调查和队列调查[J]. 北京大学学报（医学版）, 2022, 54(5): 961-970.
[3] 杨若彤,王梦莹,李春男,于欢,王小文,吴俊慧,王斯悦,王伽婷,陈大方,吴涛,胡永华. 缺血性脑卒中全基因组关联研究提示阳性基因位点与睡眠行为的交互作用[J]. 北京大学学报（医学版）, 2022, 54(3): 412-420.
[4] 陈平,黎泽明,郭怡,孙昕霙,Edwin B.FISHER. 基于大五人格理论应用潜在剖面分析探究2型糖尿病患者的用药依从性[J]. 北京大学学报（医学版）, 2021, 53(3): 530-535.
[5] 刘晓强,杨洋,周建锋,刘建彰,谭建国. 640例单牙种植术对血压和心率影响的队列研究[J]. 北京大学学报（医学版）, 2021, 53(2): 390-395.
[6] 刘欢,何映东,刘金波,黄薇,赵娜,赵红薇,周晓华,王宏宇. 血管健康指标对新发心脑血管事件的预测价值:北京血管健康分级标准的初步验证[J]. 北京大学学报（医学版）, 2020, 52(3): 514-520.
[7] 黎泽明,高敏,陈雪莹,孙昕霙. 2型糖尿病患者大五人格特征与自我管理态度的相关性[J]. 北京大学学报（医学版）, 2020, 52(3): 506-513.
[8] 孟文颖,黄琬桐,张杰,焦明远,金蕾,靳蕾. 孕早期血清维生素E水平与妊娠期高血压疾病发病风险的关系[J]. 北京大学学报（医学版）, 2020, 52(3): 470-478.
[9] 唐迅,张杜丹,刘晓非,刘秋萍,曹洋,李娜,黄少平,窦会东,高培,胡永华. China-PAR脑卒中模型在北方农村人群中预测脑卒中发病风险的应用[J]. 北京大学学报（医学版）, 2020, 52(3): 444-450.
[10] 贾子昌,李选,李小刚,曾祥柱,栾景源,王昌明,韩金涛. 机械取栓治疗急性缺血性脑卒中单中心研究[J]. 北京大学学报（医学版）, 2019, 51(2): 256-259.
[11] 谢江,李菲. 睡眠重叠综合征与糖尿病发病率的横断面调查研究[J]. 北京大学学报（医学版）, 2019, 51(2): 252-255.
[12] 王小慧，张岩，刘林枝，尚晨光. 二甲双胍与脂联素对子宫内膜癌细胞增殖的作用[J]. 北京大学学报(医学版), 2018, 50(5): 767-773.
[13] 林鸿波，陈奕，沈鹏，李小勇，司亚琴，张杜丹，唐迅，高培. 社区糖尿病患者慢性肾脏病的发病率及其危险因素[J]. 北京大学学报(医学版), 2018, 50(3): 416-421.
[14] 唐迅，张杜丹，何柳，曹洋，王晋伟，李娜，黄少平，窦会东，高培，胡永华. China-PAR模型在北方农村人群中预测动脉粥样硬化性心血管疾病发病风险的应用[J]. 北京大学学报(医学版), 2017, 49(3): 439-445.
[15] 杨志凯, 董捷, 左力. 腹膜透析总水清除量下降速率快是患者死亡的独立危险因素[J]. 北京大学学报（医学版）, 2011, 43(6): 844-848.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
ISSN 1671-167X
CN 11-4691/R
主管单位：中华人民共和国教育部
主办单位：北京大学
地址： 北京市海淀区学院路38号 北京大学医学部 《北京大学学报（医学版）》
邮编：100191
电话：010-82801551
Email： xbbjb2@bjmu.edu.cn

《北京大学学报（医学版）》
微信公众号
版权所有 © 2018 《北京大学学报（医学版）》编辑部